aDefined as eyes with at least 1 test pattern (either Humphrey Field Analyzer [HFA] 30-2 or HFA 60-4) available at baseline.
bDefined as eyes with both test patterns (HFA 30-2 and HFA 60-4) available and excluding eyes that had excessive false positive or excessive fixation loss at baseline or other irregularities invalidating the results. For HFA 30-2 test, 28 and 32 scans were excluded from ranibizumab and panretinal photocoagulation groups, respectively; for HFA 60-4 test, 30 and 31 scans were excluded, respectively.
Outlying values were truncated to 3 SDs from the mean. Error bars represent 95% confidence intervals. The orange line indicates the mean change from baseline over time censoring ranibizumab eyes after the initiation of panretinal photocoagulation (PRP) treatment. NA indicates not applicable.
eFigure 1. Mean change from baseline in the total point score from the 30-2 test pattern
eFigure 2. Mean change from baseline in the total point score from the 60-4 test pattern
eFigure 3. Mean value for the combined mean deviation from the 30-2 and 60-4 test patterns
eTable. Estimates of mean change in visual field outcomes associated with ranibizumab injections, laser treatment and time from longitudinal regression analyses of change from baseline level in multiple sensitivity analyses
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Maguire MG, Liu D, Glassman AR, et al. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2020;138(3):285–293. doi:10.1001/jamaophthalmol.2019.5939
What are the visual field (VF) changes throughout 5 years after randomized assignment to intravitreal ranibizumab or panretinal photocoagulation for proliferative diabetic retinopathy?
In this post hoc analysis of a randomized clinical trial of 234 eyes, eyes in the panretinal photocoagulation group had substantial loss of VF at 1 year and additional VF loss over time. Eyes in the ranibizumab group lost VF sensitivity after 2 years in the absence of laser treatments.
While laser treatments account for some of the VF loss over time, these data suggest that other processes may be associated with VF deterioration; however, limitations of the available data prevent more specific conclusions.
Preservation of peripheral visual field (VF) is considered an advantage for anti–vascular endothelial growth factor agents compared with panretinal photocoagulation (PRP) for treatment of proliferative diabetic retinopathy. Long-term data on VF are important when considering either treatment approach.
To further evaluate changes in VF throughout 5 years among eyes enrolled in the Protocol S clinical trial, conducted by the DRCR Retina Network.
Design, Setting, and Participants
Post hoc analyses of an ancillary study within a multicenter (55 US sites) randomized clinical trial. Individuals with eyes with proliferative diabetic retinopathy enrolled in Protocol S were included. Data were collected from February 2012 to February 2018. Analysis began in June 2018.
Panretinal photocoagulation or intravitreous injections of 0.5-mg ranibizumab. Diabetic macular edema, whenever present, was treated with ranibizumab in both groups. Panretinal photocoagulation could be administered to eyes in the ranibizumab group when failure or futility criteria were met.
Main Outcomes and Measures
Mean change in total point score on VF testing with the Humphrey Field Analyzer 30-2 and 60-4 test patterns.
Of 394 eyes enrolled in Protocol S, 234 (59.4%) were targeted for this ancillary study. Of these, 167 (71.4%) had VF meeting acceptable quality criteria at baseline (median [interquartile range] age, 50 [43-58] years; 90 men [53.9%]). At 5 years, 79 (33.8%) had results available. The mean (SD) change in total point score in the PRP and ranibizumab groups was −305 (521) dB and −36 (486) dB at 1 year, respectively, increasing to −527 (635) dB and −330 (645) dB at 5 years, respectively (P = .04). After censoring VF results after PRP treatments in the ranibizumab group, the 5-year mean change in total point score was −201 (442) dB. In a longitudinal regression analysis of change in total point score including both treatment groups, laser treatment was associated with a mean point decrease of 208 (95% CI, 112-304) dB for the initial PRP session, 77 (95% CI, 21-132) dB for additional PRP sessions, and 325 (95% CI, 211-439) dB for endolaser. No association was found between change in point score and the number of ranibizumab injections during the previous year (−9 per injection [95% CI, −22 to 3]).
Conclusions and Relevance
The limited data available from Protocol S suggest that there are factors besides PRP associated with VF loss in eyes treated for proliferative diabetic retinopathy. Further clinical research is warranted to clarify the finding.
ClinicalTrials.gov identifier: NCT01489189
Although panretinal photocoagulation (PRP) has been the standard treatment for proliferative diabetic retinopathy (PDR) for almost half a century, anti–vascular endothelial growth factor (anti-VEGF) agents provide an alternative approach that is safe and effective through at least 5 years.1 Data from the DRCR Retina Network Protocol S indicated that patients randomly assigned to either PRP or ranibizumab treatment maintained good visual acuity through 5 years with low rates of complications of PDR.1 An important difference between treatment groups was the pattern of visual field (VF) loss. Panretinal photocoagulation burns cause VF loss and the PRP group in Protocol S had large losses at 1 year,1,2 as expected, with further decline over the next 4 years. At the primary outcome annual visit of 2 years after initiation of treatment for PDR, there was little change in VF indices in the ranibizumab group; however, VF losses accumulated between 2 and 5 years such that by 5 years, the mean loss in the ranibizumab group was approximately half the amount in the PRP group.1,2 Given that loss of VF with PRP contributes to the decision in choosing between PRP or anti-VEGF monotherapy, additional post hoc analyses were undertaken to explore VF loss in both treatment groups.
Methods for the DRCR Retina Network Protocol S clinical trial have been published elsewhere1,2 (study protocol available at http://www.drcr.net). Participants were 18 years or older, had type 1 or 2 diabetes, and had at least 1 eye with PDR in the investigator’s judgement and visual acuity of 20/320 or better. A total of 394 study eyes of 305 participants were enrolled from 55 sites in the United States and were randomly assigned 1:1 to either 0.5-mg intravitreous ranibizumab or PRP treatment. Participants with 2 study eyes were randomly assigned to ranibizumab in 1 eye and PRP in the other. The study adhered to the tenets of the Declaration of Helsinki.3 Written informed consent was obtained from participants. The protocol and Health Insurance Portability and Accountability Act–compliant informed consent forms were approved by institutional review boards associated with each site.2 Data were collected from February 2012 to February 2018.
Eyes initially received the assigned treatment. Regardless of treatment assignment, eyes with center-involved diabetic macular edema (DME) and visual impairment were treated with ranibizumab at baseline; treatment of DME with ranibizumab during follow-up was at investigator discretion. The protocol required visits every 16 weeks for both groups, while participants in the ranibizumab group had additional visits every 4 to 16 weeks based on the study retreatment algorithm. Panretinal photocoagulation was allowed in the ranibizumab group if an eye met the protocol-specified failure or futility criteria. Additional PRP could be administered in the PRP group if neovascularization increased.
Annual VF testing was performed at a subset of sites. Participants had perimetry using the Humphrey Field Analyzer 30-2 (76 points) and 60-4 (60 points) test patterns, both with a size V target and FastPac testing strategy.4 A refraction was performed and used for the 30-2 testing only. Graders at the University of Iowa Visual Field Reading Center determined the validity of results. Total point (decibel) scores from each test were summed to provide a combined total point score. The combined mean deviation was the average of the mean deviation from each test pattern weighted by the number of points in the test pattern.
The main analysis was a comparison of mean change from baseline in the combined total point score among the eyes with valid fields and without excessive false positives (>33%) or fixation losses (>33%) at baseline. Outlying values were truncated to 3 SDs from the mean (18 of 491 values [3.7%]). Outcomes were analyzed with a longitudinal, mixed-effects linear regression model including baseline point score, indicator variables for presence of both eyes in the study and baseline central subfield thickness (randomization stratification factors), years after baseline, and time-dependent variables for PRP and endolaser applications and number of ranibizumab injections in the previous year. The intercept and years after treatment were considered random effects, and an autoregressive dependence of scores over time was assumed. The Akaike information criterion statistic was used to measure the fit of the model to the data. Least squares mean values for each annual visit were calculated using the baseline mean values for the total VF point score, inclusion of both eyes in the study, and central subfield thickness, and using 0 ranibizumab injections in the previous year and 0 laser treatments of any kind. All P values and confidence intervals were 2-sided. For these exploratory analyses, P values less than .05 were considered of interest. The analyses for this article were generated using SAS/STAT software, version 15.1 (SAS Institute). Analysis began June 2018.
Among 234 study eyes of 177 participants enrolled at 36 sites participating in the ancillary study, 81 of 114 eyes (71.1%) in the ranibizumab group and 86 of 120 eyes (71.7%) in the PRP group completed both test patterns with results that met the quality criteria for VF at baseline, ie, without excessive false positives, excessive fixation losses, or other irregularities invalidating the results (Figure 1). Because of missed visits or participant refusals to undergo VF testing during follow-up, eyes with results for both test patterns decreased at 5 years to 41 of 114 (36.0%) in the ranibizumab group and 38 of 120 (31.7%) in the PRP group. Within the cohort of 167 eyes with baseline VF data meeting the quality criteria, study participants who did not complete the 5-year visit (n = 48) compared with those who had 5-year VF data (n = 79) had a higher proportion of non-Hispanic African American individuals (12 [25%] vs 6 [8%]), shorter median (interquartile range) duration of diabetes (15 [11-21] vs 20 [10-24] years), worse mean visual acuity at baseline (20/40 vs 20/32) and at 2 years (20/32 vs 20/25), and worse mean deviation at baseline (−7.5 dB vs −6.6 dB) (Table 1).5 Participants who completed the 5-year visit but did not have VF testing (n = 40) compared with those with 5-year VF data (n = 79) had a higher proportion of non-Hispanic African American individuals (8 [20%] vs 6 [8%]), a lower proportion with high-risk PDR or worse PDR (8 [21%] vs 37 [47%]), and similar baseline mean visual acuity and VF indices.
Among eyes with VF data available at baseline and at least 1 follow-up visit, 4 of 69 eyes (6%) in the ranibizumab group had standard PRP and 8 (12%) had endolaser associated with vitrectomy during follow-up. In the PRP group, 38 of 74 eyes (51%) had 1 or more additional PRP sessions, with most sessions (56 of 71 [79%]) occurring within the first 2 years after randomization; 9 eyes (12%) had 1 or more endolaser sessions during vitrectomy with most eyes (7 of 9 [78%]) treated during the second year after randomization. The mean (SD) number of injections of ranibizumab among patients in the ranibizumab group who completed each annual visit without having had a PRP treatment was 7 (3) in the first year, 4 (3) in the second year, and 3 (3) in each subsequent year. The mean (SD) number of ranibizumab injections after randomization in the PRP group was 3 (4) in the first year, 2 (2) in the second year, 1 (2) in the third, 1 (1) in the fourth year, and 0 (2) in the fifth year.
At baseline, the mean (SD) combined total point score was 3487 (659) in the PRP group and 3365 (759) in the ranibizumab group; corresponding values for mean deviation were −6.4 (4.6) dB and −7.0 (5.2) dB, respectively. The mean (SD) total point score change from baseline in the PRP group was −305 (521) at 1 year and −422 (518) at 2 years, with additional loss over time through 5 years, at which the mean (SD) total point score change was −527 (635) (Figure 2). In the ranibizumab group, the mean (SD) total point score change was −36 (486) at 1 year, −23 (410) at 2 years, and −330 (645) at 5 years. As reported previously, the difference in mean VF loss between the 2 groups was significant at both 2 and 5 years.1,2 When results of VF testing after application of standard PRP or endolaser were excluded (censored) in the ranibizumab group, the mean (SD) total point score was −201 (442) at 5 years (Figure 2). The point score declined between years 3 and 5 for both the pericentral 30-2 and peripheral 60-4 test patterns for the PRP group and for the ranibizumab group with data censored after laser treatment (eFigures 1 and 2 in the Supplement).
The mean values over time for the combined mean deviation from the 30-2 and 60-4 test patterns for the same 3 groups as in Figure 2 are shown in eFigure 3 in the Supplement. The average mean deviations for the ranibizumab groups were stable over the first 3 years and decreased between years 3 and 5.
Longitudinal regression modeling was used to assess the associations of ranibizumab injections, laser treatments, and time with total point score during the follow-up period. The mean change in total point score associated with the number of ranibizumab injections in the previous year was −9 (95% CI, −22 to 3; P = .15; Table 2). Application of any type of laser treatment was associated with lower total point score, with mean changes of −208 (95% CI, −304 to −112), −77 (95% CI, −133 to −21), and −325 (95% CI, −439 to −211) associated with the initial PRP session, each additional PRP session, and each endolaser application, respectively. The model with years after baseline as a continuous variable (ie, linear slope) did not fit the data as well as the model with time as a categorical variable (difference in Akaike information criterion = 109.6). Mean change in total point score associated with time from baseline, after accounting for laser treatments and injections, was −34 (95% CI, −175 to 106) at 1 year, −48 (95% CI, −171 to 75) at 2 years, −125 (95% CI, −250 to 1) at 3 years, −168 (95% CI, −294 to −43) at 4 years, and −201 (95% CI, −327 to −74) at 5 years (P value for differences between times = .04). Similar results regarding the associations with the VF total point score of ranibizumab injections, laser treatment, and time were observed under a number of alternative approaches such as using mean deviation as the outcome instead of total point score, including eyes regardless of excessive false positives or fixation losses at baseline, excluding follow-up VF with excessive false positives or fixation losses, using only the 30-2 test pattern or using only the 60-4 test pattern (eTable in the Supplement).
Because preservation of VF sensitivity is considered an advantage of anti-VEGF monotherapy compared with PRP for treatment of PDR, the changes in VF sensitivity in eyes in both the ranibizumab group and the PRP group of Protocol S of the DRCR Retina Network were evaluated in more detail than presented in our previous reports.1,2 As expected, loss of VF sensitivity was observed in the PRP group; however, the losses observed in the ranibizumab group between years 2 and 5 were unexpected. In the ranibizumab group, there was little or no VF loss on average until after 2 years of follow-up with additional losses through 5 years; however, the magnitude of loss did not reach the level observed in the PRP group through 5 years (P = .04).1 Closer examination of the data has suggested factors that might contribute to some of the loss in VF in the ranibizumab group and raised questions about the possible influence of other factors while also revealing the limitations of the available data.
Based on the data available, there was substantial loss of VF associated with application of laser treatment for PDR, both in the pericentral field corresponding to the 30-2 testing pattern and the peripheral field corresponding in the 60-4 testing pattern. In the longitudinal model describing total VF point score loss, the amount of loss depended on the type of laser treatment applied. On average, additional PRP sessions were associated with less VF loss than an initial PRP session, and endolaser application during vitrectomy was associated with more loss than an initial PRP session. The losses may be direct and immediate effects of heavier vs lighter photocoagulation or reflections of delayed deleterious effects of the treatments, conditions associated with the persistence or return of neovascularization necessitating additional treatment, cataract progression, or, in the case of endolaser with vitrectomy, adverse effects of vitreous hemorrhage or the surgical procedure, such as cataract.
The mean value for the combined mean deviation from the 30-2 and 60-4 test pattern (eFigure 3 in the Supplement) decreased in the ranibizumab group between years 3 to 5 compared with the decrease for the total point score between years 2 and 5 (Figure 2). We have less confidence in the mean deviation results as there is some concern about the accuracy of the age-adjusted normal values for the size V target used for VF testing in this study. Owing to its relatively small size, the normative database used for the age-specific normal values may not be sufficient to provide accurate mean deviation values, especially for older and younger patients.4
After removing the VF data for eyes in the ranibizumab group after laser treatment, the average loss of VF sensitivity was less than when all VF testing during follow-up in the ranibizumab group was included (Figure 2). However, the mean total point score was still less than at baseline by approximately 200 points at 5 years, which is approximately equivalent to a decrease of 1.5 dB in mean deviation. Within this group, the loss of VF did not appear to be a constant amount each year but with more loss in later years; however, the lower number of eyes each year available for analysis limits the ability to accurately identify the pattern of VF loss over time.
Although definitive conclusions cannot be drawn from these results, there are multiple possible reasons for the progression of VF loss seen in the eyes treated only with anti-VEGF therapy in this study. One possible explanation is that progression of the underlying diabetic retinopathy is affecting VF sensitivity. There is evidence that diabetic retinal neurodegeneration progresses with duration of diabetes and may precede signs of diabetic retinopathy.6-9 Deterioration of the VF in eyes of patients with diabetes in the absence of treatment with laser or pharmacologic agents is evident by the mean deviation at baseline of approximately −6.5 dB for this cohort. Increasing retinal ischemia associated with PDR may cause further deterioration of VF sensitivity despite laser or anti-VEGF. This hypothesis is supported by the results of the CLARITY study of aflibercept vs PRP for PDR where the mean total areas of retinal nonperfusion in both treatment groups increased by 1 year after initiation of treatment.10 A second possible explanation is that the greater cumulative number of ranibizumab injections over time may have caused loss of VF sensitivity. Vascular endothelial growth factor is neuroprotective for retinal cells in a variety of animal models and suppression could theoretically cause VF loss.11,12 A final possible explanation is that ranibizumab may have protected eyes with PDR from VF loss during years 1 and 2 of the study; then, as the number of injections decreased from 7 in year 1, to 4 in year 2, to 3 in later years, the VF loss that is part of the natural history of PDR became apparent. We do not believe that prior or new DME had a strong influence on VF loss because only 4 to 12 testing locations located in the macula among the 76 locations of the 30-2 testing would likely be affected to any degree by center-involved DME and none of the 60 locations in the 60-4 test pattern would be affected.
The number of eyes with VF data available and the degree of missing data preclude definitive conclusions about VF changes in eyes treated for PDR. Among the 394 eyes enrolled in Protocol S, 234 eyes were from sites participating in the VF ancillary study. Reliable completion of VF testing proved challenging for patients, and only 167 eyes had VF testing results at baseline deemed sufficiently reliable for further analysis. Further attrition from participants missing annual visits and refusing VF testing resulted in only 79 of 234 eyes (33.8%; 20.1% of total eyes enrolled) with VF results at 5 years. Although the percentage of eyes with 5-year VF data was similar between treatment groups, ocular and participant characteristics differed between those with and without 5-year VF data (Table 1). All the reasons for attrition and differences between those with VF data and those without VF data might be associated with VF loss and could yield results that do not reflect a true estimate of VF changes in the general population of eyes that receive initial anti-VEGF vs PRP for PDR.
In summary, eyes enrolled in Protocol S had substantial VF loss at baseline. Application of scatter laser treatment, particularly endolaser during vitrectomy, was associated with large losses in VF. The VF loss in the ranibizumab group, which occurred predominantly after 2 years of follow-up, was explained only in part by laser treatments during follow-up. More precise conclusions are precluded by the limitations of the available data. Further clinical research is warranted to clarify the situation.
Corresponding Author: Adam R. Glassman, MS, Jaeb Center for Health Research, 15310 Amberly Dr, Ste 350, Tampa, FL 33647 (firstname.lastname@example.org).
Accepted for Publication: December 3, 2019.
Published Online: January 30, 2020. doi:10.1001/jamaophthalmol.2019.5939
Author Contributions: Mr Glassman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Glassman, Jampol, Baker, Bressler, Stockdale, Sun.
Acquisition, analysis, or interpretation of data: Maguire, Liu, Glassman, Jampol, Johnson, Baker, Bressler, Gardner, Pieramici, Sun.
Drafting of the manuscript: Maguire, Liu, Glassman, Jampol, Baker, Pieramici.
Critical revision of the manuscript for important intellectual content: Maguire, Liu, Jampol, Johnson, Baker, Bressler, Gardner, Pieramici, Stockdale, Sun.
Statistical analysis: Maguire, Liu.
Obtained funding: Glassman, Jampol, Bressler, Sun.
Administrative, technical, or material support: Glassman, Stockdale, Sun.
Supervision: Glassman, Jampol, Baker, Bressler, Sun.
Conflict of Interest Disclosures: Dr Maguire, Mss Liu and Stockdale, and Mr Glassman report grants from the National Institutes of Health and nonfinancial and other support (ranibizumab and funds to defray clinical site costs) from Genentech during the conduct of the study and nonfinancial and other support from Regeneron and Allergan outside the submitted work. Dr Jampol reports grants from the National Eye Institute during the conduct of the study. Dr Baker reports grants from Regeneron, Roche, Novartis, and Allergan outside the submitted work. Dr Bressler reports grants from Bayer, Genentech/Roche, Novartis, and Samsung Bioepis outside the submitted work. Dr Gardner reports grants from Zebra Biologics outside the submitted work. Dr Pieramici reports grants and personal fees from Regeneron, Genentech, Novartis, Regenxbio, and Adverum Biotechnologies outside the submitted work. Dr Sun reports grants from Jaeb Center during the conduct of the study; nonfinancial support (equipment loaned for research) from Optovue, Boston Micromachines, and Adaptive Sensory Technology; grants and nonfinancial support from Roche, KalVista Pharmaceuticals, and Boehringer Ingelheim; grants from JDRF; personal fees from Current Diabetes Reports and JAMA Ophthalmology; personal fees and nonfinancial support from Merck and Novartis; and nonfinancial support from Novo Nordisk outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, which are part of the National Institutes of Health, an agency of the US Department of Health and Human Services (grants EY14231, EY23207, and EY18817). Genentech provided ranibizumab for the study and funds to the DRCR Retina Network to defray the study’s clinical site costs.
Role of the Funder/Sponsor: The National Institutes of Health participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study nor in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Per the DRCR Retina Network Industry Collaboration Guidelines (http://www.drcr.net), the DRCR Retina Network had complete control over the design of the protocol, ownership of the data, and all editorial content of presentations and publications related to the protocol.
Group Information: DRCR Retina Network sites are listed in order by number of participants enrolled. Personnel are labeled I for study investigator, C for coordinator, V for visual acuity technician, and P for photographer. Charlotte Eye, Ear, Nose and Throat Associates PA, Charlotte, North Carolina (21 participants): David Browning, MD, PhD (I); Andrew N. Antoszyk, MD (I); Angela K. Price, MPH (C,V); Merri F. Walker (C,V); Jenna T. Herby, BS, CCRC (C,V); Christina J. Fleming, BS, CCRP (C,V); Taylor S. Jones (C,V); Brittany A. Murphy, BA, COT (C,V); Ashley A. McClain, BS, CRC (C,V); Sherry L. Fredenberg (C,V); Autumn C. Grupp, COA (V); Erica Breglio (V); Gina M. Lester, COA (V); Sarah A. Ennis (V); Kelly R. Gallagher, BA, CCRC (V); Angella K. Gentile (V); Teneisha A. Ragin (P); Susannah J. Held, BA (P); Uma M. Balasubramaniam (P); Matt Dunlap (P); Robin Kerr (P); Michael D. McOwen (P); Carol A. Shore (P); Swann J. Bojaj (P); Lynn Watson (P); Beverly O. Rowland (P); Autumn K. Finch (P); Donna McClain, COA (P); Jeff A. Kuopus, COT (P); Joan P. Mondello, COT (P); Kathryn Kimrey (P); Lisa A. Jackson (P); Loraine M. Clark, COA (P). Elman Retina Group PA, Baltimore, Maryland (16 participants): Michael J. Elman, MD (I); Henry A. Leder, MD (I); JoAnn Starr (C); Charlene K. Putzulo (C); Jennifer L. Belz (C); Twyla J. Robinson (C); Dallas R. Sandler (V); Dena Y. Salfer-Firestone, COA (V); Jennifer L. Simmons (V); Perel M. Simpson, COA (V); Alesia K McCalla (V); Teresa Coffey (V); Pamela V. Singletary, COA (V); Ashley Davis (V); Amy Thompson (V); Ashley M. Metzger (P); Daniel J. Ketner, CRA (P); Peter Sotirakos (P); Terri Cain (P). Florida Retina Consultants, Lakeland, Florida (14 participants): Scott M. Friedman, MD (I); Nader Moinfar, MD, MPH (I); Damanda F. Fagan (C,P,V); Kimberly A. Williamson (C,P,V); Katrina L. Dawson (C); Karen Sjoblom (C,V); Jacqueline Andrews (V); Paige N. Walters (V); Allen McKinney (P); Steve Carlton (P). Paducah Retinal Center, Paducah, Kentucky (14 participants): Carl W. Baker, MD (I); Ron H. Tilford, MD (I); Tracey M. Caldwell, CCRC (C); Jil D. Baker, MT, ASCP (C); Margaret J. Orr, COA (V); Lynnette F. Lambert, COT (V); Mary J. Sharp, COA (V); Tracey R. Martin, COA (V); Alecia B. Camp (P); Samantha Kettler (P); Tana R. Williams, COA (P); Kylie S. Sedberry (P). Southeast Retina Center PC, Augusta, Georgia (13 participants): Dennis M. Marcus, MD (I); Harinderjit Singh, MD (I); Siobhan O. Ortiz (C); Teresa J. Acklie (C); Geri L. Floyd (C); Courtney N. Roberts, BA (C); Amina Farooq, MD (C); Christy Coursey (V); Brook Parsons (V); Judith Hendrickson, OD (V); Thomas Bailey (V); Lindsay Allison Foster (V); Virginia Mims (V); Michele Woodward (V); Kimbi Y. Overton (P); Ken Ivey, COA (P); Jared C. Gardner (P). California Retina Consultants, Santa Barbara, California (12 participants): Dante J. Pieramici, MD (I); Alessandro A. Castellarin, MD (I); Gina Hong, BS, BA (C,P,V); Sara Esau (C,P,V); Michelle S. Hanna, BS (C,P,V); Erica D. Morasse, BA (C,P,V); Jack Giust, BS (C,P); John McDermott (C); Layne J. Bone, AS (C,V); Lisha Wan, BA (C,P,V); Melvin D. Rabena, BS (C); Sarah Fishbein (C,P,V); Timothy Do, BS (C,P); Kelly Avery (V); Jerry Smith (V); Aimee Walker (P); Nitce L. Ruvalcaba (P); Aimee H. Shook, BS (P); Susan Spaeth (P); Matthew Giust (P). Retina Research Center, Austin, Texas (12 participants): Brian B. Berger, MD (I); Chirag D. Jhaveri, MD (I); Saradha Chexal, MD (I); Daniela Mariel Wilson (C); Jenny J. Tracy, BA (C); Ivana Gunderson (C,V); Kimberly Hosein (C); Rachel A. Walsh (C); Tina A. Seidu (C); Tori Moore, BS (C); Ryan M. Reid (C,P,V); Ginger J. Manhart (C); Chelsey A. Bravenec (V); Angela N. Palacios (V); Bianca Luong (V); Dietrich Riepen (V); Brandon Nguyen (V); Ben Ostrander (P); Boris Corak, BS (P); Christopher C. Stovall (P); Yong Ren (P); Erik Rocha (P). Texas Retina Associates, Lubbock, Texas (10 participants): Michel Shami, MD (I); Sushma K. Vance, MD (I); Yolanda Saldivar (C); Keri S. Neuling, CMA, CCRC (C); Brenda K. Arrington, CRA, COT (C,P,V); Ashaki Meeks (V); Natalie R. Garcia, COA (V); Ginger K. Rhymes, COA (P); Glenn R. Gardner, CRA (P); Janet Medrano (P); Kayla Blair, CST (P). Carolina Retina Center, Columbia, South Carolina (10 participants): Jeffrey G. Gross, MD (I); Barron C. Fishburne, MD (I); Michael A. Magee, MD (I); Vincent Klapper (C,V); Joel Gross (C,P); Amy M. Flowers, BA (C,V); Christen Ochieng, BS (C,V); Riley Stroman (C,V); Angelique SA McDowell, BS (V); Hunter Matthews (P); Randall L. Price, BA (P). Fort Lauderdale Eye Institute, Plantation, Florida (10 participants): Stuart K. Burgess, MD (I); Tirso M. Lara, MD (I); Noel H. Pereda, MD (C,V); Cindy V. Fernandez, MD (C,V); Deborah Davis (V); Evelyn Quinchia (V); Karen Workman (P). Valley Retina Institute, McAllen, Texas (9 participants): Victor Hugo Gonzalez, MD (I); Rohit Adyanthaya, MD (I); Nehal R. Patel, MD (I); Roberto Diaz-Rohena, MD, FACS (I); Yesenia Salinas, CRC (C); Crystal A. Alvarez, BS (C); Amber B. Ibarra, BS (C); Ana L. Pina, BA (C); Angelina Garza, BS (C); Jessica Rodriguez (C); Gabriela Zavala, BS (C); Ruth Iracheta (C); Edna E. Cruz (C); Kethsaly J. Salinas, BS (C); Deyla Anaya (C); Isaac Cabrera (V); Tiffany Gonzalez (V); Ashley Leal (V); Yvonne Diaz (V); Tabitha Trevino (V); Rebecca R. Flores, COA (V); Christina Villegas (V); Janette Arredondo (V); Rachel Rodriguez, MA (V); Monica R. Cantu, COT (V); Maricela Garza, MA (V); Jennifer Moreno (V); Krystle R. Lozano (V); Karina Miranda, CMA (V); Hector Jasso, MA (V); Amanda L. Sandoval, MA (P); Samuel Alonso (P); Lazaro Aguero, MD (P); John Trevino (P); Santos Garza (P); Monique Montemayor, COA (P). Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan (9 participants): Thomas W. Gardner, MD, MS (I); Robin D. Ross, MD (I); Grant M. Comer, MD, MS (I); Laxmi V. Devisetty, MD (I); Pamela S. Campbell, COT, CCRP (C,V); Susan M. Sanford, RN (C); Lindsay M. Godsey, MS (C,V); Karen King, BA, CCRC (C); Tracy M. Utley, COMT (C,P,V); Linda Fournier, COA(V); Mary D. Walker, COA (V); Shannon Henderson, COA (V); Moe Hesselgrave, COA (V); Laura A. Rozek (P); Hillary Bernard (P); Timothy Steffens, CRA (P); Alexis L. Smith (P); Robert Prusak (P); Anthony Medina, CRA (P); Linda Goings (P); Joanie H. Lippincott, COA (P); Laura B. Trebesh (P); Matthew S. Lawrence, CRA (P). Retina Northwest PC, Portland, Oregon (9 participants): Mark A. Peters, MD, FACS (I); Colin Ma, MD (I); Michael S. Lee, MD (I); Paul S. Tlucek, MD (I); Brian S. Puckett (C); Stephen Hobbs (C,P,V); Pualani Smith (C); Stephanie L. Ho, BA (C,P,V); Margaret E. Charpentier (V); Marcia Kopfer, BS, COT (V); Amanda C. Milliron (V); Joe Logan, AA (P); Christine Hoerner (P). Retinal Consultants of San Antonio, San Antonio, Texas (9 participants): Calvin E. Mein, MD (I); Moises A. Chica, MD (I); Richard Gary Lane, MD (I); Sarah Elizabeth Holy, MD (I); Lita Kirschbaum, COA (C,V); Tori R. Moore, BS (C,V); Adriana A. Lopez (C); Vanessa D. Martinez (C); Jaynee Baker (C); Christa G. Kincaid (V); Elaine Castillo (P); Brenda Nakoski (P); Christopher Sean Wienecke (P); Clarissa M. Marquez (P); Sara L. Schlichting (P); Jorge Castellanos (P). Vitreo-Retinal Associates, Grand Rapids, Michigan (8 participants): Frank J. McCabe, MD (I); Brad J. Baker, MD (I); Melvyn H. Defrin, MD (I); Marie V. Lampson, COA (C,P); Aundrea S. Borelli, COT (V); Christina Cartagena (V); Elizabeth White (V); Heather Pratte, COA (V); Jennifer Risi (V); Selena A. Baron (V); Amy Paul (V). New England Retina Associates, Trumbull, Connecticut (7 participants): Gregory M. Haffner, MD (I); Sumit P. Shah, MD (I); Nauman A. Chaudhry, MD (I); Leslie D. Hurst, MS (C); Laura A. Fox (C,V); JoAnna L. Pelletier (C); Jennifer M. Matteson (C); Emiliya German (C); Shannan Moreau (C); Stephanie Esteves (V); Heather Casey (V); Kristen G. Tommaselli (V); Kristin E. Brown (V); Michelle Esler (V); Alison Fontecchio (V); Adriana N. Enxuto (V); Emily Morse, BS (P); Marissa L. Scherf (P); Marie Grace Laglivia (P); Greg McNamara (P); Angela LaPre (P); Justin A. Cocilo (P); Stefanie R. DeSantis (P). Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California (7 participants): Joseph T. Fan, MD (I); Mukesh Bhogilal Suthar, MD (I); Michael E. Rauser, MD (I); Raquel Hernandez (C,P,V); Liel Marvyn Cerdenio, BS (C,V); Anthoni Tampubolon (C,V); Brandi J. Perez (C,V); Gisela Santiago (C,V); Jacqueline V. Midgett, MPH (C); Kara E. Halsey (C,P,V); Travis D. Davison, BS (C); William H. Kiernan, OD (V); Armand Assissini (P); Diana Povero (P); Jesse Knabb, COA (P); Moises Tellez (P); Marcia Easterly (P). Retina Consultants of Houston PA, Houston, Texas (7 participants): Charles C. Wykoff, MD, PhD (I); Matthew S. Benz, MD (I); Rosa Y. Kim, MD (I); Amy C. Schefler, MD (I); David M. Brown, MD, FACS (I); Eric Chen, MD (I); James C. Major, MD (I); Tien P. Wong, MD (I); Richard H. Fish, MD, FACS (I); Diana Rodriguez (C); Amy Hutson (C); Ashley E. Chancey (C); Bylinda Vo-Le (C); Cassie Cone (C); Daniel Park (C); Stacy M. Supapo (C); Meredith Berry (C); Sadia Y. Karani (C); Garret L Twining (C); Kimberly Williamson (C); Leslie K. Kao (C); Nubia Landaverde (C); Maura A. Estes (C); Rebecca Yee (V); Heather Koger-Grifaldo (V); Veronica A. Sneed (V); Brenda Dives (V); Belinda A. Almanza (V); Melina Vela (V); Elizabeth Quellar (V); Tressa Royse (V); Tamara L. Dodel (P); Miranda F. James (P); Luis R. Salinas (P); Eric N. Kegley (P); Cary A. Stoever (P); Beau A. Richter (P). Casey Eye Institute, Portland, Oregon (6 participants): Andreas K. Lauer, MD (I); Christina J. Flaxel, MD (I); Steven T. Bailey, MD (I); Ann D. Lundquist, BA (C,V); Mitchell Schain, BS (C,V); Shelley A. Hanel, BS (C); Jennifer K. Maykoski, BS (V); Susan K. Nolte (V); Shirley D. Ira, COT (V); Chris S. Howell, BA (P); Michelle Brix (P); Jordan Barth, AA (P); Jocelyn T. Hui, BS (P); Dawn M. Ryan, CRA (P); Scott R. Pickell, BS (P); Peter N. Steinkamp, MS (P); Chiedozie Ukachukwu (P). Family Eye Group, Lancaster, Pennsylvania (5 participants): Michael R. Pavlica, MD (I); Alexandra C. Teale (C); Noelle S. Matta, COT (C,V); Christine M. Keefer (P); Alyson B. Keene (P); Cristina M. Brubaker, COA (P). Retina Associates of Cleveland Inc, Beachwood, Ohio (5 participants): Michael A. Novak, MD (I); Llewelyn J. Rao, MD (I); David G. Miller, MD (I); Jerome P. Schartman, MD (I); Joseph M. Coney, MD (I); Lawrence J. Singerman, MD (I); Susan C. Rath, PA, CCRC (C,V); Janine Davis, RN (C); John Lacombe (C,V); Larraine Stone, RN, BA, CCRC (C); Veronica A. Smith, RN (C); Mary A Ilc, COT (V); Vivian Tanner, COT (V); Cecelia Rykena, ABO-NCLE (V); Kimberly A. DuBois, LPN, CCRP (V); Kim Drury, RN (V); Tia R. Drugan, COA (V); Elizabeth McNamara, COA (P); Gregg A. Greanoff, COA, CRA (P); Trina M. Nitzsche (P); John C. DuBois, CRA (P). National Ophthalmic Research Institute, Fort Myers, Florida (5 participants): A. Thomas Ghuman, MD (I); Glenn Wing, MD (I); Ashish G. Sharma, MD (I); Paul A. Raskauskas, MD (I); Eileen Knips, RN, COA, CRA (C,P); Laura Greenhoe, BA (C); Natalie N. Torres (C); Crystal Y. Peters, CCRC (C); Cheryl Ryan (C); Cheryl Kiesel, COA, ROUB (C,P); Rebecca J. Youngblood (C); Anita H. Leslie (V); Danielle Dyshanowitz (V); Raymond K. Kiesel (P); Etienne C. Schoeman (P). Ocala Eye Retina Consultants, Ocala, Florida (5 participants): Chander N. Samy, MD (I); Robert J. Kraut, MD (I); Tammy L. Conder, BS, COA (C,P); Linsey Corso, COA (C,P); Kathy Shirley, COT (C,P); Karen Ely, COA (V); Stacey Chiguina (P); Stewart Gross (P); Vanessa Alava (P); Elizabeth Scala, COA (P); Arlene Egan (P). Medical Center Ophthalmology Associates, San Antonio, Texas (4 participants): Michael A. Singer, MD (I); Darren J. Bell, MD (I); Catherine Ellis, BS (C); Beatrice A. Guajardo (C); Judy Rittimann, COT (C); Tamara M. Urias, LVN (C); Ann-Marie Mora, OD (V); Roxanne Gomez (V); Felicia Huron (P); Celia Maria Pena (P); Vincent Segovia (P); Rosa Escobar (P). Wolfe Eye Clinic, West Des Moines, Iowa (4 participants): Kyle J. Alliman, MD (I); Jared S. Nielsen, MD (I); Tami Jo Woehl (C); Bethany George, RN (C); Marianne Parker (C); Marilyn A. Johnson (V); Jack Bowers (V); Jamie Spillman (V); Jennifer L. Coleman (V); Holly Keenan (V); Spencer D. Ridgway (P); Jay Rostvold (P); Bailey R. Bennett (P); Jodi Weier (P); Lisa M. Boender (P). Medical College of Wisconsin, Milwaukee, Wisconsin (4 participants): Judy E. Kim, MD (I); Dennis P. Han, MD (I); Thomas B. Connor, MD (I); David V. Weinberg, MD (I); William J. Wirostko, MD (I); Vesper V. Williams (C); Krissa L. Packard (C); Tracy L. Kaczanowski, MS, CCRC (C); Pat A. Winter (V); Judy Flanders, BS (V); Vicki Barwick, BS (V); Stephanie J. Moebius (P); Mara Goldberg (P); Marriner L. Altmann, CRA, CPT, OCT-C (P); Kathy J. Selchert, COT (P); Dennis B. Backes (P); Joseph R. Beringer (P); Brittany Rego (P); Hannah Sheppard (P). Joslin Diabetes Center, Boston, Massachusetts (4 participants): Paul G. Arrigg, MD (I); Paolo S. Silva, MD (I); Timothy J. Murtha, MD (I); George S. Sharuk, MD (I); Lloyd Paul Aiello, MD, PhD (I); Jennifer K. Sun, MD, MPH (I); Margaret E. Stockman (C,V); Hanna Kwak (C); Jerry D. Cavallerano, OD, PhD (V); Rita K. Kirby, MS (V); Leila Bestourous (V); Michael N. Krigman (V); Steve L. Papaconstantinou, COT (V); Elizabeth S. Weimann, COT, BS (V); Robert W. Cavicchi (P). Raj K. Maturi, MD, PC, Indianapolis, Indiana (4 participants): Raj K. Maturi, MD (I); Ashley M. Harless (C,P,V); Lorraine White (C,P); Laura A. Bleau, LPN, CRC (C,V); Carolee K. Novak, CRC (V); Abby Maple (P); Thomas Steele, CRA (P); Missy Livengood (P); Nicole Ellingwood (P); Charlotte Harris (P); Alisha Ware (P). Southeastern Retina Associates PC, Knoxville, Tennessee (4 participants): Joseph M. Googe, MD (I); Stephen L. Perkins, MD (I); Nicholas G. Anderson, MD (I); Kristina Oliver (C); Steve Morris (C); Lisa Lovelady (C); Julie Asher (C,V); Jennifer Beerbower, COA (V); Christy Berry (V); Cecile Hunt (V); Nicole Grindall, COA (V); Ann Arnold, COT (V); Patricia Coppola (V); Kathy L. Schulz, COT (V); Sarah M. Oelrich (P); Justin Walsh (P); Raul E. Lince (P); Jerry K. Whetstone (P); Erika A Oelrich (P). Denver Health Medical Center, Denver, Colorado (4 participants): Hugo Quiroz-Mercado, MD (I); Guillermo Salcedo-Villanueva, MD (C); Leif S. Ryman (C); Daniela Santos Canto, MD (C); Teresa E. Rudesyle (C); Chelsea Lynn Mastin (V); Rosemary C. Rhodes, COT (V); Carolyn J. Jackson, COT (P); Regina Victoria, COT (P). Retina-Vitreous Surgeons of Central New York PC, Syracuse, New York (4 participants): G. Robert Hampton, MD (I); Jamin S. Brown, MD (I); Laurie J. Sienkiewycz (C); Cindy J. Grinnell, RN (C); Victoria L. Gabris, RN (C); Lynn M. Kwasniewski (V); Michelle L. Manley (V); Brandi M Bellows (V); Teresa M. DeForge (P); Nicole E. Robarge (P); Peter B. Hay (P); Stefanie R. DeSantis, BS (P). University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania (3 participants): Alexander J. Brucker, MD (I); Benjamin J. Kim, MD (I); Sheri Drossner, MSW (C,V); Joan C. DuPont, CRC (C,V); Armin Farazdaghi (V); Tyrone Quarterman (V); Judy Chen (P); Michael Bodine (P); Beth Serpentine, BS (P); William Nyberg (P); Sara Morales (P); Laurel Weeney (P); Cheryl Devine (P); Jim M. Berger (P). University of Washington Medical Center, Seattle, Washington (3 participants): James L. Kinyoun, MD (I); Gurunadh Atmaram Vemulakonda, MD (I); Ian P. Luttrell (C,V); Susan A. Rath (C,V); Patricia K. Ernst, BA, COA (C,V); Francy Moses (V); Juli A. Pettingill (V); James D. Leslie, BFA (P); Ronald C. Jones (P); Brad C. Clifton (P). Bay Area Retina Associates, Walnut Creek, California (3 participants): Stewart A. Daniels, MD (I); Tushar M. Ranchod, MD (I); Craig J. Leong, MD (I); Shannon R. Earl (C); Stacey Touson, BS (C,P,V); Nicole T. Pham, BS (C); Kayla Gustavson (V); Mariana Castro (V); Melissa C. Bartlett, AAS (V); Jessica Garcia (V); Christine Fernando (V); Grace M. Marudo, AAS (P); Leah M. McNeil (P); Matthew D. Hughes, AAS (P); Betty Hom (P); Fred Hanamoto (P); Yesenia Cerna (P); Cathy Walker (P); Jose Carlos Suazo, AAS (P). Retinal and Ophthalmic Consultants PC, Northfield, New Jersey (3 participants): Brett T. Foxman, MD (I); Scott G. Foxman, MD (I); Natalie S. Mahan, COA, CRC (C,P); Chastity Mendez (C,P,V). University of Florida College of Medicine, Department of Ophthalmology, Jacksonville Health Science Center, Jacksonville, Florida (3 participants): Sandeep Grover, MD (I); Kakarla V. Chalam, MD, PhD, MBA, FACS (I); Shamim A. Haji, MD (I); Ghulam Shabbir Hamdani, MBBS, MSH, CCRP (C); Wenhua Li, MD (C,P,V); Jazzmin N. Smith (C,P); Bharani Krishna Mynampati A, PhD (C,P,V); Ashley Cowart, OD (C,V); Kumar Sambhav, MD (C,P,V); Cheryl L. White (C,V); Nicholas Freeman (P); Jose J. Carrion (P). University of Rochester, Rochester, New York (3 participants): David Allen DiLoreto, MD, PhD (I); George W. O’Gara, MBA, CCRC (C); Andrea M. Czubinski (C,V); Kari M. Steinmetz, BA, COA (C); Salina M. Tongue, AAS, COA (V); Melissa S. Keim (V); Dan A. Castillo (V); Rebecca K. Gerhart, BS (V); Rachel M. Aleese, BS, COT (V); Yvonne F. Yu (V); Gary Gagarinas, COMT, CCRA (V); Rachel Hollar (P); Patricia A. Artman, BS (P); Lynn Singer (P); Steven DeRidder (P); Laura Guzman (P); TKe Long (P); Brittany S. Richardson, BS (P); Brittany A. Bateman, BS (P); Brandi N. Deats (P); Kassandra J. Mundt, BA (P); Taylor A. Pannell, BS (P). Retina Specialists of Michigan, Grand Rapids, Michigan (3 participants): Thomas M. Aaberg, MD (I); Scott J. Westhouse, MD (I); Holly L. Vincent, COA (C,P,V); Rebecca Malone, COA, OSC (V); Casey Le Roy (P); Kathy L. Karsten, COT (P); Shymaa Mohamed (P); Kristine L. VanDerKooi, BA, COA (P); Olivia P. Rainey, BFA (P). New England Retina Associates, New London, Connecticut (3 participants): Nauman A. Chaudhry, MD (I); Emiliya German (C); Heather Casey (V); Alison Fontecchio (V); Justin A. Cocilo (P). Spokane Eye Clinical Research, Spokane, Washington (3 participants): Robert S. Wirthlin, MD (I); Eric S. Guglielmo, MD (I); Eileen A. Dittman, CCRC, RN (C,V); Dylan C. Waidelich, COA (C,P,V); Jillian N. Erstad (C,P,V); Brian G. Skea (C,P,V); Lori L. Atwood (V); Christina Owens, COT (V); Cristofer J. Garza, NCLE-AC, ABOC, COA (P); Adeline M. Stone, COT (P); Vicki M. Stanton, COT (P); Ashley Nicole Oakes, COA (P). Austin Retina Associates, Austin, Texas (3 participants): Robert W. Wong, MD (I); Peter A. Nixon, MD (I); Shelley Day, MD (I); Margaret A. Rodriguez, COA (C,P); Chris A. Montesclaros (C,P); Carrie E. Leung (C,P); Phillip V. Le (C,V); Mary Laremont (P); Cory Mangham (P); Codey L. Daus (P). Retina Associates of Florida LLC, Tampa, Florida (2 participants): Ivan J. Suner, MD (I); Marc C. Peden, MD (I); Mark E. Hammer, MD (I); Janet R. Traynom, COT (C,P); Rochelle DenBoer, LPN (C); Heidi Vargo, COT (V); Susan Ramsey (V); Debra Jeffres, RN (P); Anita Kim Malzahn (P). NorthShore University HealthSystem, Glenview, Illinois (2 participants): Manvi P. Maker, MD (I); Mira Shiloach, MS (C,V); Liza Vierneza-Castillo (P); Lynn Wasilewski (P); Courtney Kastler (P). Baylor Eye Physicians and Surgeons, Houston, Texas (2 participants): Christina Y. Weng, MD, MBA (I); Petros Euthymiou Carvounis, MD (I); Robert E. Coffee, MD, MPH (I); Annika S. Joshi, COA, CCRC (C,V); Wendy Blacutt, MD (C,V); Margaret M. Olfson, COA, CCRP (C); Karri Schuetzle, AAS, COA, CCRP (C); Cindy J. Dorenbach, COT (C,V); Pejman Hemati (C,V); April Leger, COT (V); Joseph F. Morales (P); Dana B. Barnett (P). Retina Vitreous Consultants, Monroeville, Pennsylvania (2 participants): Karl R. Olsen, MD (I); P. William Conrad, MD, PhD (I); Judy C. Liu, MD (I); Robert L. Bergren, MD (I); Pamela P. Rath, MD (I); Bernard H. Doft, MD (I); Lori A. Merlotti (C); Missy A. Forish (C,V); Mary E. Kelly (C); Holly M. Mechling (C); Jennifer L. Chamberlin, BS (C); Grace A. Rigoni (V); Veronica L. Bennett, COA (V); Julie Walter (V); Kellianne Marfisi (V); Kimberly A. Yeckel (V); Lois Stepansky (V); Christina R. Fulwylie (V); Christina M. Schultz (V); Dawn Diperna (P); David Steinberg (P); Courtney L. Foreman (P); Keith D. McBroom (P); Brandi L. Sherbine (P); Amanda Fec (P). Sarasota Retina Institute, Sarasota, Florida (2 participants): Melvin Chen, MD (I); Marc H. Levy, MD, FACS (I); Waldemar Torres, MD (I); Peggy A. Jelemensky (C,V); Tara L. Raphael (V); Mark A. Prybylski (V); Amanda S. Holland (V); Joann J. Rich (V); Ruth P. Arroyo (P); Charlotte Rodman (P); Evelyn J. Inlow (P); Mark Sneath, COA (P); Rosa Miller (P); Jim Sherry (P). Retina and Vitreous of Texas, Houston, Texas (2 participants): Joseph A. Khawly, MD (I); H. Michael Lambert, MD (I); Diana Abdelgani (C); Pam S. Miller (C,V); Valerie N. Lazarte (V); Debbie Fredrickson (V); Lorena R. Martinez (P); Colin Blank (P); Desiree Lopez (P); Donald K. Lowd (P); Jason E. Muniz (P). Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland (1 participant): Sharon D. Solomon, MD (I); Susan Bressler, MD (I); Deborah Donohue (C,V); Lisa K. Levin (C); Keisha Murray (V); Mary Frey, BSc, CCRP (V); Rita L. Denbow, MLA, COA (V); Charles Herring, CRA (P); Jacquelyn McDonald (P); Janis Graul (P); Joe Belz (P); David Emmert, BA (P); Dennis Cain, CRA (P); Nick Rhoton, AA (P); Russ Distle (P). Texas Retina Associates, Lubbock, Texas (1 participant): Gary E. Fish, MD (I); Sally Arceneaux (C,V); Brenda Sanchez (V); Karen Duignan (V); Tina M. Stanley (P); Nicholas Hesse (P); Michael Mackens (P). Retinal Consultants of Arizona, Phoenix, Arizona (1 participant): Karim N. Jamal, MD (I); Sachin Mehta, MD (I); David T. Goldenberg, MD (I); Scheleen R. Dickens (C); Jessica L. Miner, RN (C,V); Heather Dunlap (V); Lydia Saiz (V); John J. Bucci (P); Dayna Bartoli (P); Rohana Yager (P). The Retina Institute, St Louis, Missouri (1 participant): Kevin J. Blinder, MD (I); Ginny S. Nobel, COT (C); Rhonda F. Weeks, CCRC (C,V); Maria A. Stuart, COA (V); Lynda K. Boyd, COT (V); Kelly E. Pepple (V); Diana Reardon, RNA (V); Brook G. Pulliam, COA (V); Steve A. Schremp (P); Dana L. Gabel (P); Jarrod Wehmeier (P); Timothy L. Wright (P). Montefiore Medical Center, Bronx, New York (1 participant): Umar Khalil Mian, MD (I); Evelyn Koestenblatt (C); Ana Paula Morales Allende, BA (C); Rebecca L. Riemer, BS (C); Louise V. Wolf, PhD (C); Nicole Bernstein, BA (C); Irina Katkovskaya, OD (V); Erica Otoo, OD (V); Christine Kim, OD (V); Edward Miranda (P); Caroline Costa, COA (P); Kevin A. Ellerbe, COA (P); Kenneth Boyd (P). Retina and Vitreous Associates of Kentucky, Lexington, Kentucky (1 participant): Thomas W. Stone, MD (I); John W. Kitchens, MD (I); Diana M. Holcomb, COA (C,V); Jeanne Van Arsdall (V); Brenda VanHoose (V); Bryan Noel (P); Michelle Buck, BA, COT (P); Edward A. Slade, BA, CRA, COA (P). Southern California Desert Retina Consultants MC, Palm Desert, California (1 participant): Clement K. Chan, MD, FACS (I); Maziar Lalezary, MD (I); Tiana Gonzales (C); Kimberly S. Walther (C); Lenise E. Myers, COA (V); Kenneth M. Huff, COA (P). Campbell, Retinal Diagnostic Center, Campbell, California (1 participant): Amr Dessouki, MD (I); Joel M. Barra, BSBM, CCRP (C); Jessenia Perez (C); Rose Monahan (C); Thanh T. Nguyen (C); Hienmy Dang (V); Kelly To (V); Tim Kelley (P). DRCR Retina Network Coordinating Center: Jaeb Center for Health Research, Tampa, Florida (staff as of April 10, 2019): Adam R. Glassman (director and principal investigator), Roy W. Beck (executive director), Daphne Auza, Alyssa Baptista, Wesley T. Beaulieu, Claire Boyle, Sharon R. Constantine, Brian B. Dale, Simone S. Dupre, Sandra Galusic, Meagan Huggins, Paula A. Johnson, Brittany Kelly, Danni Liu, Brenda L. Loggins, Maureen Maguire, Michele Melia, Ilona Nemeth, Isoken Odia, Carin M. Preston, Cynthia R. Stockdale, Katie Stutz. DRCR Retina Network Chair: Jennifer K. Sun (2018-present), Daniel F. Martin (2018-present), Lee M. Jampol (2013-2017), Neil M. Bressler (2006-2012). DRCR Retina Network Vice Chairs: Carl W. Baker (2011-2013; 2017-present), Chirag Jhaveri (2016-2018), Mathew MacCumber (2018-present), Andrew Antoszyk (2013-2016), Susan B. Bressler (2009-2011), Scott Friedman (2009-2012), Judy Kim (2015-2017), Ingrid U. Scott (2009-2010), Jennifer K. Sun (2012-2014), John A. Wells III (2013-2015). National Eye Institute: Sangeeta Bhargava (2016-present), Eleanor Schron (2009-2015). Executive Committee: Andrew N. Antoszyk (2009; 2013-present), Carl W. Baker (2009-present), Roy W. Beck (2002-present), Sangeeta Bhargava (2016-present), Barbra Blodi (2014-present), Neil M. Bressler (2006-present; chair, 2006-2008), Susan B. Bressler (2009-present), Frederick L. Ferris III (2002-present), Adam R. Glassman (2005-present), Glenn J. Jaffe (2012-present), Lee M. Jampol (2012-present), Chirag D. Jhaveri (2016-present), Brandon Lujan (2017-present), Mathew MacCumber (2018-present), Dennis M. Marcus (2011-2012; 2018-present), Daniel F. Martin (2017-present), Raj K. Maturi (2009-2011; 2013-present), Jennifer K. Sun (2009-present). Prior members: Lloyd Paul Aiello (2002-2018; chair, 2002-2005), Abdhish Bhavsar (2007-2008; 2010-2012), Alexander J. Brucker (2009-2011), Kakarla V. Chalam (2009-2011), Ronald P. Danis (2004-2015), Matthew D. Davis (2002-2017), Michael J. Elman (2006-2018; chair, 2009 and 2012), Donald F. Everett (2002-2009), Joan Fish (2008-2009), Scott Friedman (2007-2013), Joseph Googe Jr (2009-2011), Jeffrey G. Gross (2012-2017), Diana M. Holcomb (2011-2012), Judy E. Kim (2015-2017), Andreas Lauer (2007-2008), Ashley McClain (2013), Brandi J. Perez (2013), Eleanor Schron (2009-2015), Ingrid U. Scott (2009-2010), JoAnn Starr (2009-2011), John A. Wells III (2012-2015). Data and Safety Monitoring Committee: Gary Abrams, Deborah R. Barnbaum, Harry Flynn, Kyle D. Rudser, Paul Sternberg, Sangeeta Bhargava, Ruth S. Weinstock, Stephen Wisniewski, John Connett (2003-2015), Charles P. Wilkinson (2012-2018).
Disclaimer: Dr Bressler is editor and Dr Sun is CME Editor of JAMA Ophthalmology, but they were not involved in any of the decisions regarding review of the manuscript or its acceptance.